3 New Strong Buy Ratings from Top-Rated Analysts: 04/28/2026

Make space on your watchlist: All of today’s picks have intense upside potential…

• TE Connectivity (NYSE: TEL) — Top analysts eye 25%+ upside after record Q2 beat
• Teva Pharmaceutical (NYSE: TEVA) — Unanimous Strong Buy with 45% upside and FDA catalysts ahead
• Neurocrine Biosciences (NASDAQ: NBIX) — Citi sees 89% upside on this biotech breakout

P.S. For more high-potential tickers, check out our latest video drop. 

A note from our sponsors...

The AI That Could Triple Your Money This Year

Early users could have already tripled their money every single year this AI has been live, based on the average winning trade spotted - WITHOUT having to check the news, WITHOUT watching the Fed, and WITHOUT all the stress most traders have to deal with. For now, you can try this AI yourself, completely free of charge - no email, no credit card.

Click to learn more

1. TE Connectivity (NYSE: TEL)

TE Connectivity powers the world's transportation, industrial, and communications sectors with cutting-edge connectivity and sensor solutions across global markets. After delivering record-breaking Q2 earnings — crushing estimates with 15% sales growth and 20%+ EPS growth — top-tier analysts are circling, even as the stock trades at a discount.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $214.67 — get current quote

Max 1-year forecast: $297.00

Why we're watching:

• Analyst support: Wall Street maintains strong conviction with 7 Strong Buy ratings, 2 Buy ratings, and 4 Hold ratings among 13 analysts covering the stock. See the ratings
• For example, Goldman Sachs' Mark Delaney (a top 2% rated analyst) maintains a Strong Buy rating with a $270 price target, representing +25.77% upside potential.
• Oppenheimer's Christopher Glynn (a top 6% rated analyst) sees even more upside with a $285 price target, citing the company's strong commercial momentum and transformational progress.
• Industry ranking context: TEL is currently the 2nd highest-rated stock in the Electronic Components industry, which has an Industry Rating of A. (What’s #1? See the full list here.)
• Zen Rating highlights: TEL has an exceptional Zen Rating of A or Strong Buy, putting it in a class of stocks that have historically delivered 32.52% annual returns.
• Component Grades: TEL demonstrates exceptional Safety metrics with an A grade, balanced by strong B grades in Value, Growth, and Financials, positioning the stock as a defensive growth play in the electronic components sector. See all 7 Zen Component Grades here

2. Teva Pharmaceutical Industries (NYSE: TEVA)

Teva Pharmaceutical is a global powerhouse in generics, specialty medicines, and biopharmaceuticals. With a robust pipeline, sharpened cost discipline, and multiple FDA approvals on the horizon, this pharma giant is quietly setting the stage for sustained growth — even amid market turbulence.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $30.64 — get current quote

Max 1-year forecast: $45.00

Why we're watching:

• Analyst support: Overwhelming bullish sentiment with 6 Strong Buy ratings and 1 Buy rating from 7 analysts, representing unanimous positive coverage. See the ratings
• Bank of America's Jason Gerberry (a top 15% rated analyst) maintains a Strong Buy rating with a $42 price target, suggesting over 37% potential upside in the coming year, noting that Teva is well positioned for future growth with a positive outlook on new drug approvals and strong demand in the generics market.
• Industry ranking context: TEVA is currently the 3rd highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of A.
• Zen Rating highlights: TEVA ranks in the top 5% of stocks we track based on a 115-factor fundamental check, resulting in an overall A or Strong Buy rating. 
• Component Grades: TEVA shows balanced fundamentals with B grades across Value, Growth, Momentum, Safety, and AI, though Sentiment and Financials come in at C — suggesting an attractive but not flawless value play in pharmaceuticals. See all 7 Zen Component Grades here

3. Neurocrine Biosciences (NASDAQ: NBIX)

Neurocrine Biosciences is a leader in pharmaceuticals targeting neurological, endocrine, and psychiatric disorders, anchored by its blockbuster tardive dyskinesia franchise. Fresh two-year CRENESSITY data — showing sustained glucocorticoid dose reductions while maintaining androgen control in adults with classic congenital adrenal hyperplasia — is supercharging the bull case heading into Q1 earnings.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $127.68 — get current quote

Max 1-year forecast: $242.00

Why we're watching:

• Analyst support: Strong conviction from Wall Street with 9 Strong Buy ratings, 6 Buy ratings, and 3 Hold ratings among 18 analysts covering the stock. See the ratings
• Let’s look at a few of the ratings. For one, Needham's Ami Fadia (a top 1% rated analyst) reiterated a Buy rating with a $185 price target, representing +44.89% upside potential.
• Citigroup's Yigal Nochomovitz (a top 7% rated analyst) maintains the highest price target at $242, representing an impressive +89.54% upside potential.
• Industry ranking context: NBIX is currently the 7th highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of A. (See what ranks higher here.)
• Zen Rating highlights: TEVA earns an overall A or Strong Buy rating, indicating that it has a higher chance of outperformance than 95% of the stocks in our system.
• Component Grades: NBIX demonstrates outstanding fundamentals with top-tier A grades in both Value and Financials, supported by solid B grades in Growth and AI — positioning it as a high-quality, deeply undervalued pharmaceutical growth story, though investors should note softer Momentum, Sentiment, and Safety scores. See all 7 Zen Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.